{"nctId":"NCT01177813","briefTitle":"Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes","startDateStruct":{"date":"2010-07"},"conditions":["Diabetes Mellitus, Type 2"],"count":986,"armGroups":[{"label":"BI 10773 low dose","type":"EXPERIMENTAL","interventionNames":["Drug: Placebo identical to BI10773 high dose","Drug: BI 10773","Drug: Placebo identical to Sitagliptin 100mg"]},{"label":"BI 10773 high dose","type":"EXPERIMENTAL","interventionNames":["Drug: Placebo identical to BI10773 low dose","Drug: BI10773","Drug: Placebo identical to Sitagliptin 100mg"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo identical to BI10773 low dose","Drug: Placebo identical to Sitagliptin 100mg","Drug: Placebo identical to BI10773 high dose"]},{"label":"Sitagliptin 100 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Placebo identical to BI10773 high dose","Drug: Sitagliptin","Drug: Placebo identical to BI10773 low dose"]},{"label":"BI 10773 high dose open label","type":"EXPERIMENTAL","interventionNames":["Drug: BI 10773 open label"]}],"interventions":[{"name":"Placebo identical to BI10773 high dose","otherNames":[]},{"name":"BI 10773","otherNames":[]},{"name":"BI 10773 open label","otherNames":[]},{"name":"Placebo identical to BI10773 low dose","otherNames":[]},{"name":"Placebo identical to BI10773 low dose","otherNames":[]},{"name":"Placebo identical to BI10773 high dose","otherNames":[]},{"name":"Placebo identical to Sitagliptin 100mg","otherNames":[]},{"name":"Placebo identical to Sitagliptin 100mg","otherNames":[]},{"name":"BI10773","otherNames":[]},{"name":"Sitagliptin","otherNames":[]},{"name":"Placebo identical to Sitagliptin 100mg","otherNames":[]},{"name":"Placebo identical to BI10773 low dose","otherNames":[]},{"name":"Placebo identical to BI10773 high dose","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n1. Diagnosis of type 2 diabetes mellitus prior to informed consent;\n2. Male and female patients on diet and exercise regimen who are drug-naÃ¯ve;\n3. HbA1c \\>= 7.0% and \\<= 10.0% at Visit 1 (screening) for randomised treatment; HbA1c \\> 10.0% at visit 1 (screening) for the open-label BI 10773 arm;\n4. Age \\>= 20 (Japan); Age \\>= 18 (countries other than Japan);\n5. BMI \\<= 45 kg/m2 at Visit 1 (screening);\n6. Signed and dated written informed consent by date of Visit 1\n\nExclusion criteria:\n\n1. Uncontrolled hyperglycaemia;\n2. Acute coronary syndrome (non-STEMI, STEMI and unstable angina pectoris), stroke or TIA within 3 months prior to informed consent;\n3. Indication of liver disease, either ALT, AST, or alkaline phosphatase above 3 x ULN;\n4. Impaired renal function (eGFR\\<50 ml/min);\n5. Bariatric surgery within the past two years or other GI surgeries;\n6. Medical history of cancer;\n7. Contraindications to sitagliptin;\n8. Blood dyscrasias or any disorders causing haemolysis or unstable red blood cell;\n9. Treatment with any anti-diabetes drug within 12 weeks prior to randomisation;\n10. Treatment with anti-obesity drugs or any other treatment leading to unstable body weight;\n11. Current treatment with systemic steroids or change in dosage of thyroid hormones within 6 weeks prior to informed consent or any other uncontrolled endocrine disorder except T2DM;\n12. Pre-menopausal women who are nursing or pregnant or are of child-bearing potential and not practicing an acceptable method of birth control;\n13. Alcohol or drug abuse;\n14. Intake of an investigational drug in another trial within 30 days prior to intake of study medication in this trial;\n15. Any other clinical condition that would jeopardize patients safety while participating in this clinical trial","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Glycosylated Haemoglobin (HbA1c) After 24 Weeks","description":"The term \"baseline\" refers to the last observation before the start of randomised trial treatment (or of open-label treatment for the open-label arm).\n\nIn this endpoint, the \"measured values\" show unadjusted values, whereas the statistical analyses show adjusted values. Statistics for open-label group are descriptive.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.05"},{"groupId":"OG001","value":"-0.66","spread":"0.06"},{"groupId":"OG002","value":"-0.77","spread":"0.06"},{"groupId":"OG003","value":"-0.65","spread":"0.05"},{"groupId":"OG004","value":"-3.10","spread":"0.22"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 24 in Body Weight","description":"The term \"baseline\" refers to the last observation before the start of randomised trial treatment (or of open-label treatment for the open-label arm).\n\nIn this endpoint, the \"measured values\" show unadjusted values, whereas the statistical analyses show adjusted values. Statistics for open-label group are descriptive.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.33","spread":"0.15"},{"groupId":"OG001","value":"-2.26","spread":"0.19"},{"groupId":"OG002","value":"-2.48","spread":"0.18"},{"groupId":"OG003","value":"0.17","spread":"0.18"},{"groupId":"OG004","value":"-1.93","spread":"0.44"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 24 in Systolic and Diastolic Blood Pressure (SBP and DBP)","description":"The term \"baseline\" refers to the last observation before the start of randomised trial treatment (or of open-label treatment for the open-label arm).\n\nIn this endpoint, the \"measured values\" show unadjusted values, whereas the statistical analyses show adjusted values. Statistics for open-label group are descriptive.\n\nFor blood pressure, data following changes in antihypertensive therapy is censored, in the same way that data following initiation of rescue medication is censored.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.8"},{"groupId":"OG001","value":"-3.5","spread":"1.0"},{"groupId":"OG002","value":"-3.2","spread":"0.9"},{"groupId":"OG003","value":"0.2","spread":"0.9"},{"groupId":"OG004","value":"-3.8","spread":"1.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"0.5"},{"groupId":"OG001","value":"-1.1","spread":"0.6"},{"groupId":"OG002","value":"-1.7","spread":"0.5"},{"groupId":"OG003","value":"0.4","spread":"0.5"},{"groupId":"OG004","value":"-1.5","spread":"0.8"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Confirmed Hypoglycaemic Adverse Events","description":"Confirmed hypoglycaemic events refer to all hypoglycaemic events, that had a glucose value \\<= 70 ml/dL or where assistance was required.\n\nSymptomatic hypoglycaemic events were to be reported as adverse events. Patients can be counted in more than one category.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null},{"groupId":"OG001","value":"0.4","spread":null},{"groupId":"OG002","value":"0.4","spread":null},{"groupId":"OG003","value":"0.4","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":229},"commonTop":["Hyperglycaemia","Nasopharyngitis","Dyslipidaemia","Urinary tract infection","Diarrhoea"]}}}